BioSpace News Archive

Drug Development

Regeneron Launches Phase III COVID-19 Prevention Trial with Antibody Cocktail

Regeneron Pharmaceuticals, with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), is launching Phase III trials of REGN-COV2, the company’s two-antibody cocktail for the treatment and prevention of COVID-19.

July 6, 2020
·
3 min read
·
Mark Terry
Business

Emergent and J&J Ink 5-Year COVID-19 Vaccine Manufacturing Deal

Emergent will handle contract development and manufacturing (CDMO) services in a deal that is valued at about $480 million for the first two years.

July 6, 2020
·
3 min read
·
Mark Terry
Drug Development

Immunomedics’ Trodelvy Successful in Phase III Breast Cancer Study

Immunomedics announced today that its Phase III study involving Trodelvy met its primary endpoint of progress-free survival, as well as secondary endpoints, in patients with metastatic triple-negative breast cancer who have previously received at least two prior therapies.

July 6, 2020
·
3 min read
·
Krystle Vermes
Drug Development

ObsEva’s Yselty Positive in Two Phase III Trials for Uterine Fibroids

ObsEva, based in Geneva, Switzerland and Boston, Massachusetts, announced topline data from the PRIMROSE 1 and 2 Phase III trials of Yselty (linzagolix) for uterine fibroids.

July 6, 2020
·
3 min read
·
Mark Terry
Policy

Biopharma Update on the Novel Coronavirus: July 6

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 6, 2020.

July 6, 2020
·
2 min read
·
BioSpace Editorial Staff
Business

239 Scientists Urge WHO to Reconsider Stance on COVID-19 Airborne Spread

In a forthcoming paper, 239 scientists from more than 30 countries are pushing the World Health Organization to pay more attention to the possible airborne spread of SARS-CoV-2.

July 6, 2020
·
4 min read
·
Mark Terry
Business

Companies Face Challenge of Enrolling Patients in COVID-19 Vaccine Studies

As of June 29, there were 13 vaccines against COVID-19 in human clinical trials.

July 6, 2020
·
4 min read
·
Mark Terry
Business

Small Biotech Companies Hold Their Own During Pandemic

As countries reopen businesses and move toward normalcy, emerging biotech companies in the U.S. and Europe have encountered a mixed bag of experiences.

July 6, 2020
·
6 min read
·
Joseph Constance
Business

Ortho Clinical Diagnostics Names Joseph M. Busky Chief Financial Officer

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics backed by The Carlyle Group, announced Joseph M. Busky has joined the Company as Chief Financial Officer, effective July 7, 2020.

July 6, 2020
·
2 min read
Deals

DLA Piper advises Liquidia in its acquisition of RareGen and its US$75 million follow-on offering

DLA Piper represented Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, in its acquisition of RareGen, LLC, a portfolio company of healthcare investment firm PBM Capital.

July 6, 2020
·
3 min read